Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Ph 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1 With Monovalent or Bivalent Dosing

Trial Profile

A Ph 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Safety and Immunogenicity Study of Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1 With Monovalent or Bivalent Dosing

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bivalent Norovirus vaccine-Vaxart (Primary) ; VXA G1.1 NN (Primary) ; VXA G2.4 NS (Primary)
  • Indications Norovirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Vaxart
  • Most Recent Events

    • 17 Jan 2020 Last checked against ClinicalTrials.gov: US National Institutes of Health
    • 01 Oct 2019 Status changed from active, no longer recruiting to completed, according to a Vaxart media release.
    • 01 Oct 2019 According to a Vaxart media release, data from the study will be presented at IDWeek 2019, 7th International Calicivirus Conference 2019 and 10th International Vaccines for Enteric Diseases Conference (VED 2019).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top